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The endogenous viral superantigen 7 in DBA/2 mice serves as a target antigen on syngeneic ESb-MP lymphoma cells for
allogeneic graft-vs-leukaemia reactive cells. Allogeneic viral superantigen 7 reactive Vb6
+ T cells are able to transfer graft-vs-
leukaemia reactivity and to kill speciﬁcally viral superantigen 7
+ ESb-MP tumour cells in vitro. Here we elucidate the mechanism
of this superantigen speciﬁc cell lysis. Already 10 min after co-incubation with in vitro stimulated Vb6
+ T cells, viral superantigen
7
+ ESb-MP tumour cells show an apoptotic phenotype (Annexin V-positivity, DNA-fragmentation). This extremely rapid type
of cell death is not mediated by the death inducing ligands CD95L, TRAIL and TNF but by perforin and granzyme B.
Surprisingly, neither mitochondria nor any of the known caspases appear to be involved in this type of tumour cell killing. In
contrast, nitric oxide, released by activated macrophages and endothelial cells, induces in the same tumour cells another type
of apoptosis which is much slower and involves mitochondria and caspase activation. A synergistic effect between the two
different effector mechanisms of superantigen reactive donor cytotoxic T lymphocytes and nitric oxide releasing host
macrophages and endothelial cells might explain the effective immune rejection of even advanced metastasised cancer in this
graft-vs-leukaemia animal model.
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In patients with chronic myeloid leukaemia, the adoptive transfer
of allogeneic bone marrow and additionally the use of allogeneic
donor lymphocytes have been shown to result in long-term survival
of up to 80% of the patients (Slavin et al, 1998). This favourable
graft-vs-leukaemia (GvL) effect is often associated with a risk for
the development of graft-vs-host (GvH) disease with signiﬁcant
morbidity and mortality (Mackinnon et al, 1995; Slavin et al,
1998). We have established an animal model for the investigation
of GvL and GvH reactivity of tumour-immune lymphocytes
(Schirrmacher et al, 1995). In situ activated tumour-reactive
lymphocytes from the tumour-resistant mouse strain B10.D2 are
transferred into 5 Gy irradiated late-stage ESb-MP tumour-bearing
DBA/2 mice. This leads to complete remission of the primary
tumour and to the eradication of metastases. The two strains of
mice are identical at the MHC but differ in minor histocompatibil-
ity and in Mls antigens (Schirrmacher et al, 1995, 1998). The latter
represent endogenous viral superantigens (vSAGs) which are
encoded by mouse mammary tumour virus proviruses (Mtvs) that
are integrated in murine genomes (Beutner et al, 1992). In contrast
to conventional antigens, SAGs are presented by MHC II molecules
outside the binding groove and are recognised by certain Vb-chains
of the TCR (Choi et al, 1996). Since these endogenous SAGs
behave like self-antigens, the reactive T cells are eliminated from
the T cell repertoire by intra-thymic deletion (Speiser et al,
1989). One of the best studied vSAGs is vSAG7 which is encoded
by Mtv7 and is expressed in DBA/2 mice and on syngeneic ESb-MP
tumour cells but not in B10.D2 mice (Schirrmacher et al, 2000).
vSAG7 is recognised by Vb6
+ T cells which are present in
B10.D2 but deleted in DBA/2 mice.
We previously demonstrated that Vb6
+ T cells which are trans-
ferred with other splenic lymphocytes from the donor strain
B10.D2 into tumour-bearing DBA/2 mice are able to break the
anti-tumour tolerance (Schirrmacher et al, 2000) and to inﬁltrate
the metastasised organs (Schirrmacher et al, 1995). In the liver,
these Vb6
+ T cells form close contacts with vSAG7 expressing
metastasised tumour cells (vSAG7
+ ESb-MP) and with host macro-
phages in the vicinity of metastases (Mu ¨erko ¨ster et al, 1998).
Moreover, treatment of tumour-bearing DBA/2 mice with freshly
isolated Vb6
+ T cells led to retarded tumour outgrowth and to
prolonged survival in comparison to untreated animals. In addi-
tion, Vb6
+ cells killed speciﬁcally tumour cells expressing the
endogenous vSAG7 in vitro (Schirrmacher et al, 2000).
Cytotoxic T lymphocytes (CTL) kill their target cells via apopto-
sis by different mechanisms, for instance, via CD95-CD95L
interaction (Henkart, 1994; Ka ¨gi et al, 1994) or via the release of
cytolytic granules containing perforin and granzymes upon contact
with the target cell (Ka ¨gi et al, 1994; Pinkoski et al, 2000). Other
molecules which can induce apoptosis especially in tumour cells
are TNF-a and TNF-related apoptosis inducing ligand (TRAIL)
(Wiley et al, 1995). After triggering the respective death receptor
a cascade of caspases is activated, which ﬁnally leads to DNA-frag-
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The apoptotic process can also implicate changes in the mitochon-
dria that leads to the loss of the mitochondrial transmembrane
potential (Dcm) (Ushmorov et al, 1999; Kroemer and Reed,
2000). Granzymes (Ebnet et al, 1991) which belong to the family
of serine proteases are also found to induce DNA-fragmentation,
for instance by activating caspase-3 (Pinkoski et al, 2000). Yet,
several recent reports indicate that induction of apoptosis and
the subsequent DNA-fragmentation do not necessarily involve the
activation of caspases (Thomas et al, 2000).
SAGs are a collection of bacterial and viral proteins with potent
immunostimulatory properties. The targeting of them to tumour
cells has become an interesting new concept to augment endogen-
ous anti-tumour reactivity but little is known so far about the
mechanisms involved (Choi et al, 1996). This study aimed to inves-
tigate how vSAG7 activated T lymphocytes kill SAG expressing
tumour cells and to obtain more insights into the mechanism of
SAG speciﬁc tumour cell lysis and GvL activity.
MATERIALS AND METHODS
Animals and cell lines
B10.D2 mice (Olac, Bicester, UK) were kept under speciﬁc patho-
gen free conditions and were used at the age of 6–8 weeks. All
animal experiments were performed according to the standards
required by the UKCCCR Guidelines. Eb is a chemically induced
T cell lymphoma (L5178Y/E) of DBA/2 mice. ESb-MP is a sponta-
neous high metastatic adhesion variant of Eb and arose most likely
after fusion of Eb cells with a host macrophage (Larizza et al,
1984). Jurkat is a human leukaemia T cell line, BL60 is a human
leukaemia B cell line and U937 is a human promonocytic cell line.
Cell lines were maintained in 5% CO2 at 378C in RPMI-1640
containing 10% FCS (both Life Technologies, Eggenstein,
Germany). In some experiments, Vb6
+ T cells were primed by
injecting 5610
4 ESb-MP tumour cells in PBS into the ear pinna
of B10.D2 mice. Animals were sacriﬁced 9 days after injection.
Abs and other reagents
The rat-anti-mouse Vb6 mAb was used as culture supernatant
(clone 44-22-1) (Payne et al, 1988). The anti-APO-1 antibody
(Trauth et al, 1989) is directed against human (hu) CD95. Hu
TRAIL-R2-Fc, hu TNF-R2-Fc and hu CD95-Fc were used in the
blocking experiments (Walczak et al, 1997, 1999). Leucine Zipper
(LZ)-TRAIL, TNF-a and LZ-CD95L were used for induction of
apoptosis (Walczak et al, 1999). All human reagents are also reac-
tive to murine cells (Walczak et al, 1999). Human IgG was
purchased from Sigma (Deisenhofen, Germany). Recombinant
(rec.) human IFN-g was obtained from Biomol (Hamburg,
Germany). Annexin V-FITC was obtained from R&D systems
(Wiesbaden, Germany). The following caspase inhibitors were
purchased from Bachem (Heidelberg, Germany): ZVAD-fmk (Z-
Val-Ala-DL-Asp-ﬂuoromethylketone) and IETD-CHO (Ac-Ile-
Glu-Thr-Asp-aldehyde (pseudo acid). JC1 (5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethyl-benzimidazol-carbocyanine iodide) was from
Molecular Probes (Eugene, OR, USA). Concanamycin A and gran-
zyme B inhibitor (Z-AAD-CMK) were obtained from Calbiochem
(Bad Soden, Germany). To evaluate apoptotic effects of nitric oxide
(NO), glycerol trinitrate (GTN; Merck; Darmstadt, Germany) was
used.
Isolation of Vb6
+ T cells via magnetic beads
Vb6
+ T cells were isolated as previously described (Mu ¨erko ¨ster et al,
1998). Spleen cells from B10.D2 mice were incubated with rat-anti-
Vb6 mAbs and with magnetic beads-conjugated anti-rat IgG isotype
Abs (Dynal, Hamburg, Germany). Cells were separated via a Dynal-
magnet. The purity of the positively selected Vb6
+ T cells was 488%.
In some experiments, CD4
+ or CD8
+ T cells were isolated by deple-
tion of CD8
+ or CD4
+ T cells by Dynabeads-conjugated anti-mouse
CD8 or Dynabeads-conjugated anti-mouse CD4 (both Dynal)
respectively. Then CD4
+Vb6
+ and CD8
+Vb6
+ T cells were isolated
as previously described (Mu ¨erko ¨ster et al, 1998). After isolation,
CD8
+Vb6
+ T cell population contained 0.4% CD4
+ cells and the
population of CD4
+Vb6
+ T cells 0.3% CD8
+ cells.
Mixed lymphocyte tumour cell culture for induction of
cytotoxic actitivity
Isolated Vb6
+ T cells from normal or immunised B10.D2 mice were
incubated with 100 Gy g-irradiated (Gammacell 1000, Ottawa, Cana-
da)Vb6negativespleencells(usedasAPC)andESb-MPorEbtumour
cells for 4 days. Cytotoxic acticity of in vitro stimulated Vb6
+ T cells
were tested either by a
51Cr-release-assay or by FACS analysis.
51Cr-release-assay ESb-MP and Eb target cells were labelled
with 0.2 mCi
51Cr sodium chromate (Amersham, Braunschweig,
Germany) in RPMI-1640 medium with 30% FCS for 90 min at
378C. Vb6
+ effector T cells were incubated with target cells (effec-
tor:target ratio 10:1) in 96-well round bottom plates (Renner,
Dannstadt, Germany) for 4 h at 378C. Radioactivity released in
supernatants was measured by a g-counter (LKB-Wallac, Freiburg,
Germany) as described (Schirrmacher et al, 2000). In all experi-
ments, an effector:target ratio of 10:1 was used. This ratio has
been previously shown to be an optimal (Schirrmacher et al, 2000).
Determination of cytotoxicity via ﬂow cytometry
Effector cells (Vb6
+ T cells) were incubated with target ESb-MP cells
(10:1 ratio) in 6-well plates for different periods of time (10–
240 min). To determine which death receptors could be involved in
the induction of apoptosis, ESb-MP cells were treated with 1 or
10 mgm l
71LZ-TRAIL,1 mgm l
71LZ-CD95L,TNF-aor10 mgm l
71
control IgG for 4 h without or with 24 h pre-incubation with IFN-g.
Asacontrolforinductionofapoptosis,eitherESb-MPcellswereincu-
bated with 0.5 mM GTN for 24 h or Jurkat cells were treated with
1 mgm l
71anti-APO-1/Protein A(10 ng ml
71,Sigma)or1 mgm l
71
LZ-CD95L, BL60 cells were treated with 1 mgm l
71 LZ-TRAIL and
U937 cells were treated with TNF-a overnight to induce apoptosis.
To block apoptosis in ESb-MP cells, the following reagents were used:
hu TRAIL-R2-Fc (10 mgm l
71), hu CD95-Fc (10 mgm l
71), hu TNF-
R2-Fc (10 mgm l
71), hu IgG1 as isotype control (10 mgm l
71),
Concanamycin A (10 nM), granzyme B inhibitor (20 mM), ZVAD-
fmk (25 mM) and IETD-CHO (25 mM). Treatment of effector and
target cells with the respective reagent started 15–60 min before the
co-incubation. As a positive control, 1–30 mgm l
71 CD95-Fc, TNF-
R2-Fc and TRAIL-R2-Fc were used to block apoptosis in Jurkat,
BL60andU937 cells.Afterremovalofeffectorcells,ESb-MPcellswere
washed,detached from the plates,and cytotoxicity was determined by
staining with 1 mgm l
71 propidium iodide (PI) which was added to
the cells 5 min before measurement.
Target cell apoptosis
Apoptosis was assessed either by Annexin V/PI staining (Koopman
et al, 1994) or by determining DNA-fragmentation (Nicoletti et al,
1991). After co-incubation with effector cells, 5610
5 ESb-MP
target cells were either resuspended in binding buffer (R&D
systems), 50 ng ml
71 Annexin V and 1 mgm l
71 PI or treated with
a hypotonic solution (0.1% sodium citrate, 0.1% Triton X-100)
containing 50 mgm l
71 PI overnight. Jurkat cells were incubated
in the hypotonic solution containing PI and DNA-fragmentation
was measured as described above. Target cell death and apoptosis
were analyzed by ﬂow cytometry using a FACScan analyzer with
CellQuest software (BD Bioscience, Heidelberg, Germany).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 828–836Cytoﬂuorometric analysis of mitochondrial
transmembrane potential (Dcm)
Dcm was measured with JC1 as described (Salvioli et al, 1997). JC1
is a cyanine dye which accumulates in the mitochondrial matrix
under the inﬂuence of the Dcm. In the presence of a high Dcm,
JC1 forms aggregates which have characteristic absorption and
emission spectra so that cells are detectable as FL1
7 and FL2
+.
5610
5 ESb-MP tumour cells were treated with 5 mgm l
71 JC1
for 20 min at 48C followed by FACScan analysis. As a control,
Jurkat cells were treated with 1 mgm l
71 anti-APO-1 mAb cross-
linked by 10 ng ml
71 Protein A for 12 h followed by incubation
with JC1 as described above.
Detection of perforin in Vb6
+ T cells
Isolated Vb6
+ T cells were stimulated either with ESb-MP or with
Eb cells and APCs or were left without any stimulation. After 4
days supernatants were taken and centrifuged by 500 r.p.m. for
5 min. The pellet containing Vb6
+ T cells were washed with PBS
and centrifuged on siliconised glass slides (Sigma). After drying,
slides were ﬁxed in acetone for 10 min at room temperature
followed by washing in PBS. To avoid nonspeciﬁc binding, slides
were treated with 1% normal goat serum for 15 min followed by
incubation with the rat-anti-mouse perforin mAb (Alexis, Gru ¨n-
berg, Germany) for 45 min. After washing, slides were treated
with a goat-anti-rat antibody conjugated with alkaline phosphatase
(AP). Then slides were washed with water, counterstained with
hemalaun (Sigma) and mounted with glycerol-gelatin (Merck).
The substrate for the development of AP consisted of 6.3 ml5 %
Neufuchsin (Sigma) or 2 mg Fast Blue (Sigma) in 16 ml4 %
sodium nitrite (Fluka, Buchs, Switzerland), 2 mg naphthol-As-Bi-
phosphate (Sigma) in 20 ml N,N-dimethylformamide (Merck)
and 3 ml of 0.05 M l
71 Tris-HCl-buffer, pH 8.7 containing 1 mM
levamisole (Sigma). As negative control either the ﬁrst antibody
was omitted or an isotype matched control antibody was used.
Both stainings revealed no staining.
RESULTS
Activated Vb6
+ T cells kill vSAG7
+ ESb-MP tumour cells by
induction of apoptosis
Vb6
+ T cells, stimulated for 4 days with tumour cells and spleen
cells as APC were able to kill vSAG7
+ ESb-MP tumour cells while
vSAG7
7 Eb tumour cells were hardly lysed (Figure 1A). Experi-
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Figure 1 Cytotoxicity towards vSAG7
+ tumour cells generated by stimulated Vb6
+ T cells in vitro.( A)V b6
+ T cells were isolated from B10.D2 mice
which were either immunised with ESb-MP cells or remained untreated (18 in vivo). Then, Vb6
+ T cells were stimulated for 4 days either with irradiated
vSAG7
7 Eb or with vSAG7
+ ESb-MP cells and APC (28 in vitro) and tested for cytotoxicity towards Eb or ESb-MP target cells (effector:target ratio 10:1) in
a4h
51Cr-release assay. The mean+standard deviation of triplicates of two independent experiments are shown. (B) CD4
+Vb6
+, CD8
+Vb6
+ and total
Vb6
+ T cells were isolated from non-immunised B10.D2 mice, puriﬁed and stimulated with irradiated ESb-MP and APCs for 4 days. Then effector cells were
co-cultured with target ESb-MP cells for 2 h, and tumour cell lysis was determined by PI staining and FACScan analysis. The mean+standard deviation from
2–4 independent experiments are shown.
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+ T cells into CD4
+ and CD8
+ T
cells revealed that both T cell subpopulations induced cell death in
ESb-MP target cells (Figure 1B).
CTLs directed to conventional antigens consisting of peptide/
MHC complexes kill their target cells via apoptosis (Henkart,
1994; Ka ¨gi et al, 1994). To determine whether vSAG7 reactive
Vb6
+ T cells are able to induce apoptosis, we assessed the death
of vSAG7
+ ESb-MP cells after co-incubation with stimulated
Vb6
+ T cells by two different methods. Figure 2A shows the
kinetics of apoptosis measured by Annexin V staining/PI staining.
After 10 min, 21% of the ESb-MP cells were Annexin V
+ indicating
that they were in the early phase of apoptosis. Additionally, at this
time point, 26% were Annexin V
+/PI
+, a phenotype speciﬁc for the
late stage of apoptosis. The maximal amount of apoptotic cells
(63%) was detected after 20 min and remained at this level until
240 min of coincubation. Changes in the forward/side scatter
which are also typical for apoptosis started as well after 10 min
of coincubation of effector and target cells (data not shown). When
measuring oligonucleosomal DNA-fragmentation, 45% of apopto-
tic ESb-MP cells were observed after 10 min of coculture (Figure
2B). The maximal level of apoptotic cells was reached after
30 min. Taken together, these observations reveal that Vb6
+ T cells
are able to rapidly induce apoptosis in vSAG7
+ ESb-MP tumour
cells.
Induction of apoptosis in ESb-MP cells is caspase-
independent and does not involve mitochondrial damage
Caspases are known as main effector enzymes responsible for the
initiation of DNA-fragmentation and the typical morphological
changes in apoptosis (Henkart, 1994; Krammer, 1998). To analyse
the involvement of caspases in this rapid vSAG7-mediated tumour
cell lysis, we added either ZVAD-fmk (a broad spectrum caspase
inhibitor) or IETD-CHO (a speciﬁc inhibitor of caspase 8) to
the coculture of Vb6
+ T cells and ESb-MP tumour cells. As shown
in Figure 3, ZVAD-fmk and IETD-CHO blocked almost completely
the death of Jurkat cells which were treated with anti-CD95 mAbs.
In addition, ZVAD-fmk also inhibited NO-mediated apoptosis in
ESb-MP cells. In contrast, ZVAD-fmk and IETD-CHO did not
inﬂuence signiﬁcantly the Vb6
+ T cell mediated apoptosis in
ESb-MP cells. Thus Vb6
+ T cells were able to induce apoptosis
in vSAG7
+ ESb-MP tumour cells in a caspase-independent manner.
The dye JC1 is known as a marker for changes in the Dcm
which can be associated with apoptosis (Salvioli et al, 1997). To
evaluate whether mitochondria are involved in the induction of
vSAG7 mediated apoptosis in ESb-MP cells, we performed JC1
staining of ESb-MP cells after co-incubation with Vb6
+ T cells
for different periods of time. In cells with intact mitochondria
and high Dcm, JC1 forms so called J-aggregates that are associated
with a large shift in emission (590 nm=Fl 1). In Jurkat cells which
were treated with anti-CD95 mAbs for 12 h the involvement of
mitochondria could be clearly detected (Figure 4). In contrast no
changes in Dcm were observed during 4 h co-culture of Vb6
+ T
cells with ESb-MP tumour cells (Figure 4). Staining with 3,3'-
dihexyloxacarbocyanine iodide (DiOC6) and dihydroethidine
(HE), which are used to determine changes in Dcm and the
production of reactive oxygen species (ROS), respectively
(Ushmorov et al, 1999) also showed no mitochondrial alterations
during Vb6
+ T cell-mediated apoptosis in ESb-MP tumour cells
(data not shown). In contrast, NO, another inducer of apoptosis
in these cells, stimulated mitochondrial changes (data not shown).
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Figure 3 Vb6
+ T cell induced apoptosis in ESb-MP cells is caspase-independent. Stimulated Vb6
+ T cells were coincubated with ESb-MP tumour cells
(effector:target ratio 10:1) for 4 h or treated with 0.5 mM GTN (NO). Jurkat cells were stimulated with an anti-APO-1 (CD95) mAb/Protein A for 12 h. In
some cultures, 25 mM ZVAD-fmk or 25 mM IETD-CHO were added. As a control, ESb-MP cells and Jurkat cells were cultured without Vb6
+ T cells and
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Figure 2 Stimulated Vb6
+ T cells induce apoptosis in vSAG7
+ ESb-MP
tumour cells. In vitro stimulated Vb6
+ T cells were co-incubated with ESb-
MP cells in a ratio of 10:1 for different periods of time and stained either
with Annexin V-FITC and 1 mgm l
71 PI (A) or were treated with a hypo-
tonic solution containing 50 mgm l
71 PI overnight to determine DNA-frag-
mentation (B). Untreated cells showed no changes in the amount of
apoptotic cells during coincubation. Apoptosis was determined by FACS-
can analysis. One representative experiment out of four (A) or three
(B) independent experiments is shown.
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induction of apoptosis in ESb-MP cells
Several death receptors and their respective ligands have been
shown to be involved in the induction of apoptosis (Ka ¨gi et al,
1994; Wiley et al, 1995). The most common are TRAIL-R1+2/
TRAIL, CD95/CD95L and TNF-R1+2/TNF. We tested whether
ESb-MP cells were sensitive towards the apoptosis-inducing poten-
tial of CD95L, TRAIL and TNF-a. Figure 5A shows the positive
controls: CD95L was able to induce apoptosis in Jurkat cells,
TRAIL induced apoptosis in BL60 and TNF-a induced apoptosis
in U937 cells. In each cell line, apoptosis could be blocked using
soluble Fc-fusion proteins against the respective ligands. In
contrast, ESb-MP tumour cells were not sensitive towards any of
these ligands, even after IFN-g stimulation for 24 h since cytotoxi-
city was not increased in comparison to untreated ESb-MP cells
(Figure 5B). Furthermore, blocking with TRAIL-R2-Fc, CD95-Fc
and TNF-R2-Fc did not signiﬁcantly affect cell lysis of ESb-MP
target cells by stimulated Vb6
+ T cells (Figure 5C). Treatment with
the isotype matched Ig control increased slightly but not signiﬁ-
cantly the number of apoptotic ESb-MP cells. We conclude that
Vb6
+ T cells induce apoptosis in ESb-MP tumour cells indepen-
dently of CD95L, TRAIL and TNF-a.
Vb6
+ T cells induce cytotoxicity in ESb-MP cells through
perforin/granzyme B
Perforin/granzymes are able to induce apoptosis in a death recep-
tor-independent manner (Ka ¨gi et al, 1994; Trapani et al, 1998;
Pinkoski et al, 2000). Figure 6A shows that Vb6
+ T cells stimulated
with vSAG7
+ ESb-MP cells for 4 days expressed perforin while no
expression of perforin was found in Vb6
+ T cells from control
cultures without stimulation or stimulated with vSAG7
7 Eb cells.
Figure 6B shows the effects of treatment of Vb6
+ T effector cells
and ESb-MP target cells with Concanamycin A, an inhibitor of
perforin or of treatment with an inhibitor of granzyme B or a
combination of both. Concanamycin A alone did not inhibit target
cell lysis while treatment with the granzyme B inhibitor led to a
signiﬁcant reduction of apoptosis. Treatment with both inhibitors
almost completely prevented the lysis of ESb-MP cells (from 35
to 5% apoptosis, Figure 6B). Together, these data indicate that
vSAG7 stimulated expression of perforin in Vb6
+ T cells. These
activated cells induced apoptosis in ESb-MP tumour cells via
released perforin and granzyme B.
DISCUSSION
We have recently identiﬁed a tumour associated endogenous
vSAG7 as a new target antigen for allogeneic GvL reactivity in a
murine tumour model (Schirrmacher et al, 2000). In DBA/2 mice,
vSAG7 behaves as a strong tolerogen leading to central deletion of
SAG-reactive Vb6
+ T cells during thymic maturation. While the
DBA/2 derived Eb T lymphoma cells did not express this SAG,
the spontaneous metastatic variant ESb and its adhesion variant
ESb-MP expressed endogenous mouse mammary tumour provirus
(Mtv)- typical intracisternal A-particles (IAP), Mtv7 orf/SAG
message and vSAG7 protein at the cell surface (Schirrmacher et
al, 2000). MMTV and IAPs have been suggested to be associated
with tumorigenicity and progression towards increased malignancy
(Schirrmacher et al, 1998). We previously reported that the allo-
geneic MHC identical mouse strain B10.D2 in contrast to DBA/2
was able to strongly reject ESb and ESb-MP tumours and that
vSAG7 reactive Vb6
+ T cells were involved in this GvL reactivity
(Schirrmacher et al, 2000).
In this study, we investigated the mechanism of tumour cell
destruction in vitro by vSAG7 reactive Vb6
+ T cells. We show here
that Vb6
+ T cells kill vSAG7
+ tumour cells via release of perforin
and granzyme B. Interestingly, this form of cell death is indepen-
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Figure 4 Vb6
+ T cell-induced apoptosis in ESb-MP cells does not involve changes in Dcm. ESb-MP cells remained untreated (light line) or were cocul-
tured with stimulated Vb6
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changes in Dcm by JC1 staining (FL1). Upon incubation of Jurkat cells with anti-APO-1 mAb, FL2 did not signiﬁcantly change, whereas FL1, which indicates
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mitochondria. It has been previously reported that vSAG7 can
induce IFN-g production by speciﬁcally primed CD8
+ T cells but
fails to trigger cytotoxicity (Herrmann et al, 1992). However, in
contrast to Herrmann et al (1992), we ﬁnd that vSAG7 stimulates
Vb6
+ T cells to express perforin and to kill vSAG7
+ target cells.
This kill is SAG-speciﬁc and occurs in several tumour cells that
express this endogenous viral superantigen (Schirrmacher et al,
2000). Interestingly, this SAG speciﬁc CTL activity is mediated
via both CD8
+Vb6
+ and CD4
+Vb6
+ T cells.
Bacterial SAG have been shown to trigger CD8
+ T cell clones
that are speciﬁc for other antigens (e.g. inﬂuenza virus peptides),
but in these systems the exerted cytotoxicity was mediated via
the CD95/CD95L system (Fuller and Braciale, 1998). Sundstedt et
al (1998) showed that injection of staphylococcal enterotoxin A
into perforin-deﬁcient mice led to less depletion of B-cells than
in control mice. This depletion was due to the release of perforin
by CD8
+ T cells. In GvL and GvH reactivity, a role for both
systems (granule exocytosis as well as CD95/CD95L) was reported
(Miwa et al, 1999; Yasukawa et al, 2000). It was thus of interest to
elucidate the mechanism by which allogeneic Vb6
+ T cells kill
vSAG7
+ tumour cells.
TNF-a and CD95L play a crucial role in the activation induced
cell death (AICD) of mature T cells (Dhein et al, 1995; Zheng et al,
1995) whereas TRAIL has been shown to induce apoptosis mainly
in tumour cells (Wiley et al, 1995; Walczak et al, 1999) but also in
normal human hepatocytes, astrocytes and keratinocytes (Jo et al,
2000). ESb-MP tumour cells were not sensitive towards any of
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bation of effector and tumour cells did not inﬂuence the cytotoxic
reactivity of Vb6
+ T cells.
The perforin/granzyme system is involved in the cytotoxic reac-
tivity of CD8
+ T cells (Ka ¨gi et al, 1994; Pinkoski et al, 2000).
Recently, perforin has been shown to play a role in AICD of T cells
in an allogeneic transplantation model (Spaner et al, 1999). In our
model, Vb6
+ T cells showed a high perforin expression after 4 days
of in vitro stimulation. The lysis of ESb-MP tumour cells was
almost completely inhibited by the perforin (concanamycin A)
and granzyme B inhibitors. Interestingly, treatment with granzyme
B inhibitor but not with concanamycin A alone inhibited target cell
lysis. This might be due to the fact that membrane damage induced
by perforin does not directly cause target cell death, but facilitates
the entry of granzymes into the cell (Shresta et al, 1999; Trapani et
al, 1998). Granzyme B, however, can also enter the cell via the
cation-independent mannose 6-phosphate/insulin-like growth
factor receptor (Motyka et al, 2000), which might explain our
observations.
The vSAG7 mediated tumour cell lysis was very fast. This is in
accordance with other observations demonstrating that granzyme
B, in contrast to granzyme A, is responsible for a rapid cytotoxic
effect (Dre ￿nou et al, 1999). We cannot exclude that granzyme A
might also be active in ESb-MP cells, since application of the gran-
zyme B inhibitor alone did not completely block apoptosis.
However, there is evidence that granzyme A and B do not synergize
but act independently of each other (Shresta et al, 1999).
The requirement of caspases as the main effector enzymes in the
initiation of the apoptotic cascade is still a matter of debate (Kram-
mer, 1998; Pinkoski et al, 2000). Several recent reports indicate that
induction of apoptosis and subsequent DNA-fragmentation do not
neccessarily involve the activation of caspases (Beresford et al,
1999; Dre ￿nou et al, 1999). vSAG7 speciﬁc Vb6
+ T cells could kill
ESb-MP tumour cells independently of caspases since blocking with
ZVAD-fmk and IETD-CHO did not lead to an inhibition of apop-
tosis in ESb-MP cells. In contrast, NO-induced apoptosis in these
tumour cells required caspase activity. Beresford et al (1999)
showed that cytolysis mediated by granzyme B was caspase inde-
pendent whereas DNA-fragmentation was caspase-dependent. In
contrast, in our model blocking with caspase inhibitors inﬂuenced
neither cytolysis nor DNA-fragmentation (data not shown).
The question arises how granzyme B may lead to DNA cleavage
without activation of caspases. It was reported that granzyme B
directly cleaves caspase substrates such as poly (ADP-ribose) poly-
merase, the catalytic subunit of DNA-dependent protein kinases
and NuMA to bring about apoptotic changes in cells (Froelich et
al, 1996; Andrade et al, 1998). Moreover, granzyme B induced
the processing of DFF45/ICAD in a caspase-independent fashion
resulting in DNase activation and DNA fragmentation (Thomas
et al, 2000). In addition, granule-mediated cell death can proceed
independently of caspases through a non-nuclear pathway (Sarin
et al, 1997). These pathways seemed to be important for cells that
are infected by viruses which are able to postpone cell death by
caspase inhibitors like crmA (Zhou et al, 1997). This might explain
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which virus-like particles and proviral genes are expressed
(Mu ¨erko ¨ster et al, 1998).
The involvement of mitochondria in apoptosis was described
for different apoptotic agents (Kroemer and Reed, 2000). We
reported previously that NO-mediated apoptosis in human
leukaemia cells is associated with mitochondrial damage (i.e., a
degradation of major mitochondrial lipid cardiolipin and cyto-
chrome c release into the cytosol) followed by an activation of
caspase-9 and caspase-3 (Ushmorov et al, 1999). Furthermore,
we found that NO produced by activated Kupffer cells during
adoptive immunotherapy with GvL-reactive T cells contributed
to apoptosis in metastatic ESb-MP tumour cells in the liver
(Mu ¨erko ¨ster et al, 2000). We showed also that this cell death
can be induced by a mitochondria-dependent mechanism driven
by CD40-CD40L interactions (Mu ¨erko ¨ster et al 2000). In contrast,
vSAG7 mediated apoptosis in ESb-MP cells occurred indepen-
dently of mitochondria since staining with JC1, DiOC6 and HE
revealed no mitochondrial damage.
In conclusion, we show that vSAG7 speciﬁc T cells rapidly
induce apoptosis in vSAG7
+ tumour cells via perforin and gran-
zyme B which occurs without involvement of mitochondria and
independently of caspases. This CTL activation leads to increased
tumour resistance and can be used for cellular therapy and to
break immunological tumour tolerance (Schirrmacher et al,
2000). These results support the importance of granule-mediated
CTL lysis of tumour cells together with apoptosis induced by
NO releasing host macrophages and endothelial cells for an effec-
tive antitumour response in vivo during adoptive immunotherapy.
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